VISEN Pharmaceuticals (HKG:2561)
Hong Kong · Delayed Price · Currency is HKD 19.04
-0.06 (-0.31%)
Sep 18, 2026, 4:08 PM HKT
VISEN Pharmaceuticals Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Cash & Equivalents | 505.81 | 632.65 | 203.59 | 347.78 | 626.46 |
Cash & Short-Term Investments | 505.81 | 632.65 | 203.59 | 347.78 | 626.46 |
Cash Growth | -37.24% | 210.75% | -41.46% | -44.48% | - |
Accounts Receivable | 34.9 | 0.17 | - | - | - |
Other Receivables | - | 0.93 | 1.77 | 4.09 | 1.45 |
Receivables | 34.9 | 1.1 | 1.77 | 4.09 | 1.45 |
Inventory | 55.95 | 1.53 | - | - | - |
Other Current Assets | 202.18 | 306.78 | 17.22 | 22.25 | 83.69 |
Total Current Assets | 849.44 | 942.05 | 222.57 | 374.12 | 711.59 |
Property, Plant & Equipment | 7.74 | 7.7 | 11.16 | 13.26 | 17.16 |
Other Intangible Assets | 1.16 | 1.07 | 0.05 | 0.57 | 1.42 |
Other Long-Term Assets | 28.81 | 26.48 | 60.04 | 55.85 | 11.1 |
Total Assets | 887.16 | 977.3 | 293.82 | 443.8 | 741.27 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Accounts Payable | 33.92 | 5.2 | 11.12 | 1.01 | 27.98 |
Accrued Expenses | - | 24.31 | 22.54 | 29.85 | 25.48 |
Short-Term Debt | 170.12 | 170.12 | - | - | - |
Current Portion of Leases | 2.85 | 2.58 | 2 | 2.55 | 4.67 |
Current Income Taxes Payable | - | 1.94 | 2.67 | 1.85 | 2.57 |
Current Unearned Revenue | - | - | - | 2.9 | 2.9 |
Other Current Liabilities | 5.29 | 6.81 | 13.87 | 13.67 | 23.74 |
Total Current Liabilities | 212.17 | 210.96 | 52.19 | 51.82 | 87.34 |
Long-Term Leases | 3.74 | 4.29 | 0.36 | 1.1 | 1.33 |
Total Liabilities | 215.91 | 215.24 | 52.55 | 52.92 | 88.67 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Common Stock | 0.08 | 0.08 | 0.07 | 0.07 | 0.07 |
Additional Paid-In Capital | - | 2,487 | 1,523 | 1,523 | 1,523 |
Retained Earnings | - | -1,867 | -1,614 | -1,431 | -1,182 |
Treasury Stock | -3.21 | -0 | -0.01 | -0.01 | -0.01 |
Comprehensive Income & Other | 674.38 | 141.53 | 331.55 | 298.91 | 311.07 |
Shareholders' Equity | 671.25 | 762.05 | 241.28 | 390.88 | 652.61 |
Total Liabilities & Equity | 887.16 | 977.3 | 293.82 | 443.8 | 741.27 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Total Debt | 176.71 | 176.99 | 2.36 | 3.65 | 6 |
Net Cash (Debt) | 329.1 | 455.66 | 201.23 | 344.13 | 620.46 |
Net Cash Growth | -59.10% | 126.44% | -41.53% | -44.54% | - |
Net Cash Per Share | 3.03 | 4.40 | 2.15 | 3.68 | - |
Filing Date Shares Outstanding | 109.58 | 109.04 | 9.34 | 9.34 | - |
Total Common Shares Outstanding | 109.58 | 109.04 | 9.34 | 9.34 | - |
Working Capital | 637.27 | 731.09 | 170.39 | 322.3 | 624.25 |
Book Value Per Share | 6.13 | 6.99 | 25.83 | 41.85 | - |
Tangible Book Value | 670.08 | 760.99 | 241.22 | 390.31 | 651.19 |
Tangible Book Value Per Share | 6.11 | 6.98 | 25.83 | 41.79 | - |
Machinery | - | 1.76 | 1.56 | 1.53 | 1.59 |
Leasehold Improvements | - | 1.17 | 0.28 | 1.76 | 3.66 |